MAKO Surgical weakness a buying opportunity, says Piper Jaffray Piper Jaffray attributes yesterday's pullback in shares of MAKO Surgical to commentary from surgeons and industry contacts at the AAOS annual meeting regarding Blue Belt Technology, a smaller but widely known competitor in robotic surgery for orthopaedics. Piper views the concerns as unwarranted and recommends using the pullback in MAKO shares as a buying opportunity. The firm reiterates an Overweight rating on the stock with a $23 price target.
News For MAKO From The Last 14 Days
Check below for free stories on MAKO the last two weeks.